Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results

• Published in: Cutaneous and ocular toxicology Vol. 40; no. 4; p. 326
• Main Authors: Savur, Fatma, Kaldırım, Havva, Atalay, Kürşat, Korkmaz, Şafak
• Format: Journal Article
• Language: English
• Published: England 02.10.2021
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Choroid - diagnostic imaging; Choroid - drug effects; Choroid - pathology; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - pathology; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea - diagnostic imaging; Macula Lutea - drug effects; Macula Lutea - pathology; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Macular Edema - pathology; Male; Middle Aged; Ranibizumab - administration & dosage; Receptors, Vascular Endothelial Growth Factor - administration & dosage; Recombinant Fusion Proteins - administration & dosage; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; choroidal thickness; macular thickness; Diabetic macular edema
• ISSN: 1556-9535
• DOI: 10.1080/15569527.2021.1949338

To evaluate the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection on central choroidal thickness (CCT), central macular thickness (CMT) and best-corrected visual acuity (BCVA) in diabetic macular edema (DME). Retrospective, cohort analysis of 90 eyes of 90 patients receiving anti-VEGF therapy for DME. In patients' records, measurements of CCT, CMT, and BCVA before treatment and at 2 years after treatment were recorded. Using enhanced-depth imaging optical coherence tomography (EDI-OCT) images, choroidal thickness and macular thickness measurements were recorded in the subfoveal area and 1 mm nasal to 1 mm temporal to the central foveal area. The baseline and final CMT and CCT values measured from all three quadrants were analyzed statistically. Mean age of the patients was 59.60 ± 9.78 (range, 40-77) years. Mean baseline nasal-CT 226.4 ± 52.5 µm, central-CT 243.2 ± 51.1 μm and temporal-CT 224.6 ± 47.9 μm. Mean final nasal-CT 220.0 ± 50.2 µm, central-CT 235.3 ± 53.6 μm, temporal-CT 220.5 ± 48.1 μm (  = 0.122,  = 0.056,  = 0.184, respectively). Mean baseline nasal- MT 385.3 ± 67.7, central-MT 345.5 ± 119.7 μm and temporal-MT 365.0 ± 64.9 μm. Mean final nasal-MT 359.6 ± 59.2 µm, central-MT 306.2 ± 98.4 μm and temporal-MT 353.4 ± 63.3 μm (  = 0.001,  = 0.002,  = 0.234, respectively). The BCVA improved from 0.52 ± 0.44 logMAR at baseline to 0.38 ± 0.33 at final (  = 0.002). After treatment of diabetic macular edema with intravitreal anti-VEGF injection, CMT and BCVA improved significantly, but CCT did not decrease significantly.